Company profile
ASSEMBLY BIOSCIENCES, INC.
NASDAQ:ASMBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Imdusiran Sodium | phase2 | — | 2 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (22)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05569941 | phase1 | completed | 2022-11-11 | 2023-04-12 | Assembly Biosciences | A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects |
| NCT03576066 | phase2 | completed | 2018-06-11 | 2019-07-05 | Assembly Biosciences | A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection |
| NCT03577171 | phase2 | completed | 2018-06-19 | 2019-06-21 | Assembly Biosciences | A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV) |
| NCT04781647 | phase2 | terminated | 2021-02-18 | 2022-12-02 | Assembly Biosciences | A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection |
| NCT04454567 | phase2 | terminated | 2020-11-11 | 2021-04-08 | Assembly Biosciences | A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors |
FDA applications (0)
No records yet.